Login / Signup

Is "end of life" a special case? Connecting Q with survey methods to measure societal support for views on the value of life-extending treatments.

Helen MasonMarissa CollinsNeil McHughJon GodwinJob N J A van ExelCam DonaldsonRachel Mairi Baker
Published in: Health economics (2018)
Preference elicitation studies reporting societal views on the relative value of end-of-life treatments have produced equivocal results. This paper presents an alternative method, combining Q methodology and survey techniques (Q2S) to determine the distribution of 3 viewpoints on the relative value of end-of-life treatments identified in a previous, published, phase of this work. These were Viewpoint 1, "A population perspective: value for money, no special cases"; Viewpoint 2, "Life is precious: valuing life-extension and patient choice"; and Viewpoint 3, "Valuing wider benefits and opportunity cost: the quality of life and death." A Q2S survey of 4,902 respondents across the United Kingdom measured agreement with these viewpoints; 37% most agreed with Viewpoint 1, 49% with Viewpoint 2, and 9% with Viewpoint 3. Regression analysis showed associations of viewpoints with gender, level of education, religion, voting preferences, and satisfaction with the NHS. The Q2S approach provides a promising means to investigate how in-depth views and opinions are represented in the wider population. As demonstrated in this study, there is often more than 1 viewpoint on a topic and methods that seek to estimate that averages may not provide the best guidance for societal decision-making.
Keyphrases
  • decision making
  • cross sectional
  • randomized controlled trial
  • mental health
  • systematic review
  • case report
  • quality improvement
  • adverse drug